13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001773206
Total reported value
$2.5B
$2.5B
77 檔
9.0%
At the close of Q1 2024, Integral Health Asset Management, LLC disclosed equity holdings valued at approximately $2.5B, spread across 77 reported holdings.
During Q1 2024, Integral Health Asset Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 5.71% | -0.39% | EXIT | |
| 2 | INSM | Insmed Inc | Stock-Healthcare | 4.53% | -4.99% | +414.29% | |
| 3 | THC | Tenet Healthcare CORP | Stock-Healthcare | 4.15% | +1.22% | NEW | |
| 4 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.81% | -0.13% | +60.00% | |
| 5 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.93% | -2.82% | -35.71% | |
| 6 | MRK | Merck & Co. Inc. | Stock-Healthcare | 2.88% | -0.66% | — | |
| 7 | EHC | Encompass Health CORP | Stock-Healthcare | 2.68% | — | +40.00% | |
| 8 | WBA | Walgreens Boots Alliance Inc | Stock-Other | 2.62% | — | +18.18% | |
| 9 | ELV | Elevance Health Inc | Stock-Healthcare | 2.41% | -0.29% | +150.00% | |
| 10 | ABBV | Abbvie Inc | Stock-Healthcare | 2.28% | — | -20.59% | |
| 11 | UHS | Universal Health Services-b | Stock-Healthcare | 2.12% | — | +78.57% | |
| 12 | NVS | Novartis Ag-sponsored Adr | Stock-Healthcare | 2.02% | -0.59% | — | |
| 13 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.99% | -0.67% | EXIT | |
| 14 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.96% | — | +90.91% | |
| 15 | ✓ | Longboard Pharmaceuticals In | Stock-Other | 1.95% | — | +8.33% | |
| 16 | HUM | Humana Inc | Stock-Healthcare | 1.93% | — | — | |
| 17 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.92% | +0.05% | +66.67% | |
| 18 | BRKR | Bruker CORP | Stock-Healthcare | 1.92% | +0.36% | NEW | |
| 19 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.85% | -0.77% | EXIT | |
| 20 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.85% | — | +50.00% | |
| 21 | ACLXGBX | Arcellx Inc | Stock-Other | 1.65% | — | +59.38% | |
| 22 | CRL | Charles River Laboratories | Stock-Healthcare | 1.63% | — | — | |
| 23 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 1.52% | -2.15% | -32.00% | |
| 24 | RGNX | Regenxbio Inc | Stock-Other | 1.49% | -0.22% | +133.85% | |
| 25 | PEN | Penumbra Inc | Stock-Healthcare | 1.45% | — | +75.00% | |
| 26 | VERA | Vera Therapeutics Inc | Stock-Other | 1.44% | -0.11% | — | |
| 27 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.41% | — | +62.50% | |
| 28 | ICLR | ICON Public Limited Company | Stock-Healthcare | 1.40% | — | +28.57% | |
| 29 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 1.39% | — | — | |
| 30 | CI | THE Cigna Group | Stock-Healthcare | 1.35% | — | — | |
| 31 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 1.32% | — | -5.88% | |
| 32 | DXCM | Dexcom Inc | Stock-Healthcare | 1.29% | -0.53% | EXIT | |
| 33 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.26% | +0.53% | +110.00% | |
| 34 | SWAVUSD | Shockwave Medical Inc | Stock-Other | 1.21% | — | — | |
| 35 | AVTR | Avantor Inc | Stock-Healthcare | 1.19% | — | +150.00% | |
| 36 | COR | Cencora Inc | Stock-Healthcare | 1.13% | +0.34% | NEW | |
| 37 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 1.09% | — | — | |
| 38 | COO | Cooper Cos Inc/the | Stock-Healthcare | 1.04% | -0.51% | EXIT | |
| 39 | EXK | Exact Sciences CORP | Stock-Materials | 0.96% | — | — | |
| 40 | SANA | Sana Biotechnology Inc | Stock-Other | 0.91% | -0.16% | — | |
| 41 | NARIUSD | Inari Medical Inc | Stock-Other | 0.89% | — | +100.00% | |
| 42 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.87% | +0.05% | -57.14% | |
| 43 | RGEN | Repligen CORP | Stock-Healthcare | 0.85% | — | -9.09% | |
| 44 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 0.85% | — | — | |
| 45 | ELAN | Elanco Animal Health Inc | Stock-Healthcare | 0.83% | -0.63% | EXIT | |
| 46 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.82% | — | — | |
| 47 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 0.80% | — | -28.57% | |
| 48 | EVH | Evolent Health Inc - A | Stock-Other | 0.76% | — | — | |
| 49 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 0.74% | — | — | |
| 50 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.74% | — | -33.33% |
According to official SEC Form 13F filings, Integral Health Asset Management, LLC reported a total U.S. public equity portfolio value of $2.5B across 77 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including VKTX, INSM, THC) accounted for 9.0% of total reported equity market value during Q1 2024.
During Q1 2024, Integral Health Asset Management, LLC's top holdings by market value included VKTX (5.7%)、INSM (4.5%)、THC (4.2%). The largest single position, VKTX, represented 5.7% of total portfolio value.
In Q1 2024, Integral Health Asset Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.